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ABSTRACT
Objective: Even though the generic medicines are considered to be a cheaper option compared to the branded medicines in India, there is a need 
to study the price disparity among the generic medicines. Hence, the present study aims to evaluate the price disparity in generic medicines under 
Government Scheme in India.
Methods: It was found that there were 101 generic medicines approved at a fixed price for procurement under the Central Government Health 
Services scheme. The prices of these medicines were searched for their availability as well as for current price in Bureau of Pharma PSUs of India 
(under Jan Aushadhi scheme) website.
Results: The major category of the generic medicine were antibiotics (53.45%) followed by nonsteroidal anti-inflammatory drugs (10.89%) and 
cardiovascular (6.93%) drugs. It was evident from the result obtained by comparing the prices across categories that there were both positive and 
negative deviations.
Conclusion: It was very much evident from the results of the mean of differences that even though fixed price contracts being in place, there is a price 
disparity in the generic drug prices seen under Government Scheme.
Keywords: Generic medicine Price, Central government health scheme, Jan aushadhi, India.
INTRODUCTION
Medicines are considered as one of the essential expenses of an Indian 
household. In the current scenario, multinational companies and large 
pharmaceutical companies are manufacturing branded medicines 
which are usually expensive and not affordable for the middle and lower 
section people of India. There is also brand price variation among the 
available medicines [1]. When these medicines are available to the public 
as generic medicines at a lower cost, similar health-care benefits can be 
achieved as that of the branded medicines [2,3]. Branded medicines 
are available at higher costs because there is more spending on the 
promotion and research of the branded medicines. Generic medicine use 
is promoted to encourage proper medicine use which otherwise maybe 
not possible with costly branded medicines [4]. Generic drugs usually 
have the same efficacy as the branded medicines; the bioequivalence of 
generic drugs is proved to be similar to that of the branded medications. 
Still, the price of branded medicines is high when compared to generic 
medicines due to the better promotion of branded medicines [5]. To 
make the medicines more affordable to the people, the Department of 
Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government 
of India, has launched the Jan Aushadhi scheme for the availability of 
generic medicines at affordable prices [6]. There are two schemes; 
one is the provision of generic medicines through Central Government 
Health Services (CGHS) under Directorate General of Health Services, 
Ministry of health and family welfare and the other is Bureau of Pharma 
PSUs of India (BPPI) under the Department of Pharmaceuticals, which 
coordinates marketing of generic medicines through Jan Aushadhi 
Stores (JAS). The Jan Aushadhi generic medicine prices under BPPI are 
claimed to be low when compared to generic medicine prices under 
CGHS. The sales of the medications from the JAS stores are minimal 
because of the price disparity and quality perception of the generics by 
the people when compared to the branded medicines [7].
Objective
Even though the generic medicines are considered to be a cheaper 
option compared to the branded medicines in India, there is a need 
to study the price disparity among the generic medicines. Hence, the 
present study aims to evaluate the price disparity in generic medicines 
under Government Scheme in India.
METHODS
Inclusion criteria
The present study included CGHS official website and BPPI official 
website for the comparison of Jan Aushadhi scheme medicine prices to 
that of the generic medicine prices available in India [8,9].
Data collection and analysis
The starting phase involved detailed study of the websites of CGHS 
generic medicine prices and BPPI which coordinates marketing of 
generic medicines through Jan Aushadhi stores; research articles and 
official websites were also studied. It was found that there were 101 
generic medicines approved with a fixed price for procurement under 
the scheme. The availability of Jan Aushadhi medicines to that of the 
generic medicines already present was studied. CGHS generic medicine 
price and BPPI Jan Aushadhi store generic medicine price were studied. 
Then, the comparative evaluation of prices of the 85 generic medicines 
was done to find the disparities. The results were presented descriptively 
in the form of the mean of difference ± standard deviation (SD).
RESULTS
All the medicines of the BPPI Jan Aushadhi scheme were classified 
according to their therapeutic classes into several categories.
The price information and availability were also studied. All the 
medicines of the BPPI Jan Aushadhi website were arranged according 
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to the therapeutic category. The mean of the difference between the 
CGHS generic medicine price and Jan Aushadhi store generic medicine 
price was studied. Then, the comparative evaluation of prices of the 85 
generic medicines was done to find the price disparities. The results 
were presented descriptively in the form of the mean of difference ± 
SD. 85 generic medicine prices of the BPPI Jan Aushadhi scheme were 
compared with that of the CGHS generic medicine prices, the percentage 
of medicines in every therapeutic category of the Jan Aushadhi is given 
in Table 1.
The major category of the generic medicines were antibiotics (53.45%) 
followed by nonsteroidal anti-inflammatory drugs (10.89%) and 
cardiovascular (6.93%) drugs. The medicine prices were compared 
across the category, both negative and positive deviations were 
observed. The mean difference in the prices of the top three therapeutic 
segments is shown in Fig. 1.
It was very much evident from the results of the mean of differences 
that even though fixed price contracts being in place, there is a price 
disparity in the generic drug prices seen under Government Scheme. 
The medicine prices of CGHS more than BPPI are shown in Table 2 and 
where BPPI prices more than CGHS are shown in Table 3.
DISCUSSION
The role of the medicines is huge in protecting, maintaining, and 
restoring people’s health. Reasonable prices of medicines are an 
important concern globally and nationally. According to literature 
searched and studied, it was observed that no studies were carried 
out on a comparison of BPPI Jan Aushadhi price to that of the CGHS 
generic medicine prices. This study reveals the deviations of prices 
among BPPI Jan Aushadhi medicine prices and generic medicine prices 
under CGHS. The Jan Aushadhi scheme under BPPI was launched as 
a major initiative claiming a reduction in prices of generic medicines. 
The deviations observed in this pricing are not appropriate when 
referred to the main motto of the scheme, which was the availability 
of generic medicines at lower prices. A serious question is regarding 
pricing of medicines in JAS; it would not be available cheaper for 
certain therapeutic categories.
CONCLUSION
As there is price disparity exist among the generic prices of the drugs 
supplied through Government Schemes in India, there is a need to find 
the proper reasons for the same development of standard procedures 
to reduce these differences.
AUTHORS’ CONTRIBUTION
Pradeep M Muragundi: Involved in study conception, design and 
analysis, interpretation of data, and critical revision of the prepared 
manuscript. Reena Shaik: Involved in literature search, acquisition of 
data, drafting of manuscript, and revision of the manuscript. Both of the 
authors read and accepted the article.
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of interest.
Table 1: Therapeutic category of the BPPI medicines included in 
the study










NSAIDs: Nonsteroidal anti-inflammatory drugs, BPPI: Bureau of Pharma PSUs 
of India
Table 2: Generic medicine where Central Government Health Services prices are more than BPPI




Category Unit Difference 
in rupees
1 Aceclofenac+paracetamol tablet 100 mg+325 mg Rs. 8.50 Rs. 5.70 NSAIDs 10 −2.8
2 Metronidazole tablet I.P 200 mg Rs. 4.55 Rs. 2.00 Anti-Malarial 10 −3.24
3 Amoxycillin capsule I.P 500 mg Rs. 28.03 Rs. 26.25 Antibiotics 10 −1.78
4 Amoxycillin oral suspension I.P 125 mg/5 ml 60 ml bottle Rs. 17.27 Rs. 14.84 Antibiotics 1 −2.43
5 Chloroquine phosphate tablet I.P approximately equivalent to 155 mg base Rs. 8.14 Rs. 4.90 Antibiotics 10 −3.24
6 Cefoperazone injection I.P 1000 mg vial Rs. 35.08 Rs. 31.20 Antibiotics 1 −3.88
7 Cefotaxime sodium injection I.P 250 mg Rs. 13.01 Rs. 7.88 Antibiotics 1 −5.13
8 Ceftriaxone injection I.P 250 mg vial Rs. 17.33 Rs. 11.80 Antibiotics 1 −5.53
9 Ceftriaxone injection I.P 1000 mg Rs. 33.60 Rs. 23.98 Antibiotics 1 −9.62
10 Meropenem injection I.P 1000 mg Rs. 295.13 Rs. 255.41 Antibiotics 1 −39.72
BPPI: Bureau of Pharma PSUs of India, NSAIDs: Nonsteroidal anti-inflammatory drugs
Table 3: Generic medicines where BPPI prices are more than Central Government Health Services
Sl. No Name of the medicines CGHS price BPPI price Category Unit Difference in rupees
1 Piperacillin and tazobactam injection 4000 mg+0.5 mg Rs. 98.28 Rs. 167.18 Antibiotics 1 68.9
2 Cefuroxime axetil tablet I.P 500 mg Rs. 103.62 Rs. 128.86 Antibiotics 10 25.24
3 Ceftazidime injection I.P 500 mg vial Rs. 27.86 Rs. 44.33 Antibiotics 1 16.47
4 Ceftazidime injection I.P 250 mg vial Rs. 20.49 Rs. 34.92 Antibiotics 1 14.43
5 Cephalexin capsule I.P 500 mg Rs. 37.62 Rs. 51.34 Antibiotics 10 13.72
6 Cefuroxime axetil tablet I.P 250 mg Rs. 52.92 Rs. 66.37 Antibiotics 10 13.45
7 Clotrimazole cream/ointment 2% Rs. 6.54 Rs. 18.00 Antibiotics 1 11.46
8 Ceftazidime injection I.P 1000 mg vial Rs. 56.89 Rs. 66.83 Antibiotics 1 9.94
9 Amoxycillin and cloxacillin capsules 250 mg+250 mg Rs. 25.00 Rs. 34.64 Antibiotics 10 9.64
10. Roxithromycin tablet 150 mg Rs. 17.62 Rs. 25.20 Antibiotics 10 7.58
BPPI: Bureau of Pharma PSUs of India
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Fig. 1: Mean of difference in prices for top three therapeutic segments. Standard deviations: Coefficient of variations±1.26 (Bureau of 
Pharma PSUs of India>Central Government Health Services [BPPI>CGHS]); antibiotic drugs ±13.53 (BPPI>CGHS) and ±9.21 (CHGS>BPPI); 
nonsteroidal anti-inflammatory drugs ±3.51 (BPPI>CGHS) and ±1.23 (CGHS>BPPI)
